Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← All stories
IndustryJune 22, 2026

Meta-Analysis Compares Weight Loss Efficacy Across Tirzepatide, Semaglutide, and Liraglutide

A new meta-analysis compared weight loss outcomes for three GLP-1 receptor agonists: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza). The study evaluated clinical efficacy data across the three drug classes to determine comparative effectiveness for weight management. The findings provide evidence that could inform prior authorization criteria, formulary placement, and medical policy for obesity treatment in Medicaid managed care plans. Many state Medicaid programs have restricted or excluded coverage of anti-obesity medications due to cost, making comparative effectiveness data particularly relevant for coverage and utilization management decisions.

Why it mattersComparative effectiveness data on GLP-1 medications directly impacts formulary design, prior authorization protocols, and medical policy for obesity treatment coverage in Medicaid managed care plans facing mounting utilization and cost pressure.

Pharmacy · Managed Care

Read the full article at thehill.com →
Share this briefing

You might also like

← All stories

Get the daily briefing.